Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that the efficacy of cangrelor
(combined with usual care) is superior to that of usual care, in subjects requiring
percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality,
myocardial infarction (MI), and ischemia-driven revascularization (IDR).